World Heart Corp

World Heart — Investor Presentation (August 2011)

32 slides from World Heart's investor presentation, Aug 4, 2011

  1. Slide 1: Investor Presentation

    Investor Presentation August 3, 2011

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Statements contained in this presentation, including those pertaining to clinical research, commercialization plans, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that cou

  3. Slide 3: Presenters/Management Team

    Presenters/Management Team Name Prior Experience Years Experience Alex Martin Chief Executive Officer Edwards Lifesciences: President, North America Johnson & Johnson (Cordis): SVP, International Morgan Brown EVP & Chief Financial Officer Lifetree Clinical Research: SVP & CFO NPS Pharmaceuticals: VP

  4. Slide 4: WorldHeart Highlights

    WorldHeart Highlights Two advanced Ventricular Assist Device programs MiFlow TM VAD – Fully magnetically levitated miniature rotary blood pump; designed to provide long-term circulatory support for earlier-stage heart failure with minimally invasive implant PediaFlow® – Fully magnetically levitated

  5. Slide 5: Heart Failure Device Market Segments

    Class I (1.7M) Class II (1.6M) Class III (1.4M) Heart Failure Device Market Segments American College of Cardiology Consensus Report on MCS 2000 for class size. Class IV (0.36M) Resynchronization Therapy Cardiac 100,000 Pts $9 Billion Potential Market BTT LVAD Destination Therapy (DT) 4,000 Pts $360

  6. Slide 6: Market Needs

    Market Needs Better Clinical Outcomes Stroke, bleeding, infections and device failures Less invasive implantation Smaller device Non-sternotomy implant Minimal by-pass time Improved user convenience and device interface Easier to use Remote monitoring / diagnostic capabilities Smaller peripherals Fu

  7. Slide 7: Current Technologies Have Not Effectively Addressed Complication Rates

    Complication Rates Heartmate II (BTT) 1 Heartmate II (DT) 2 HeartWare (BTT) 3 HeartWare (BTT) (Per Patient Year) 3 Current Technologies Have Not Effectively Addressed Complication Rates 1 – FDA Summary of Safety and Effectiveness Data, 2008. 2 – Slaughter MS, et al. Advanced Heart Failure Treated wi

  8. Slide 8: Recent Article on Acquired von Willebrand Syndrome

    Recent Article on Acquired von Willebrand Syndrome Acquired von Willebrand Syndrome in Patients with an Axial Flow Left Ventricular Assist Device Anna L. Meyer, Doris Malehsa, Christoph Bara, Ulrich Budde, Mark S. Slaughter, Axel Haverich and Martin Strueber Circ Heart Fail published online Aug 25,

  9. Slide 9: Recent Article on Acquired von Willebrand Syndrome – cont.

    Recent Article on Acquired von Willebrand Syndrome – cont. European Journal of Cardio-thoracic Surgery 35 (2009) 1091-1093 Case Report Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device Doris Malehsa, Anna L. Meyer, Christoph Bara, Mart

  10. Slide 10: Preliminary Results of Independent Investigator Biomarker Study

    Preliminary Results of Independent Investigator Biomarker Study 1 PRE ON LVAD ON VAD ON LVAD ON LVAD POST Levacor ® - Preliminary Performance Evaluation In Independent Investigator Biomarker Study The blood handling characteristics of Levacor ® demonstrate reduced impact on von Willebrand Factor (“V

  11. Slide 11: Proprietary Product Design

    Proprietary Product Design 2nd Generation 3rd Generation 4th Generation Axial Flow Pumps (~10,000 rpm) Jarvik (Jarvik Heart) HeartMate II (Thoratec) Centrifugal Flow Pump (2 – 3,000 rpm) HVAD (HeartWare) DuraHeart (Terumo) * Next Gen Devices MVAD (Heartware) Heartmate III (Thoratec) Heartmate X (Tho

  12. Slide 12: MiFlow Overview

    MiFlow™ Overview MiFlow VAD is Designed with Following Key Features: Fully magnetically levitated rotor Miniaturized profile (approximately the size of a AA battery) Wide operating range (2 L/min to 6 L/min) Pump integrated within inflow cannula tip Minimal blood / device surface interface Innovativ

  13. Slide 13: Key Features

    Key Features Fully magnetically levitated rotor: Designed for optimized flow path (wide clearances and reduced shear rates) Designed to improved blood handling (bleeding, pump thrombosis and strokes) Designed to preserve von Willebrand factor Miniaturized Profile Designed to allow non-sternotomy pla

  14. Slide 14: Key Features

    Key Features Pump integrated within inflow cannula tip Designed to significantly reduce inflow path surface area Designed to improve device placement and orientation Minimal blood / device surface interface Designed to minimize foreign body blood interaction and inflammatory response Innovative peri

  15. Slide 15: PediaFlow VAD (Basis for MiFlow VAD)

    PediaFlow VAD (Basis for MiFlow VAD) Small size Full magnetic levitation Simplest (single axis) Bearingless No wear mechanisms Simple blood path (no secondary flow path) Inflow Outflow Rotor Stator blades Impellor blades

  16. Slide 16: PediaFlow Prototype Development

    PediaFlow Prototype Development PF1 – Proof of principle Implants to 17 days PF2 – Hemodynamic optimization Implants to 70 days PF3 – Miniaturized pump Implant of 72 days

  17. Slide 17: In Vivo Results – PF1

    In Vivo Results – PF1 Post-explant device analysis First chronic animal study – 6 Days No thrombus deposition on pump surfaces Impeller Blades Stator vanes Pump Housing

  18. Slide 18: In Vivo Results – PF2

    In Vivo Results – PF2 Hemolysis Fibrinogen

  19. Slide 19: In Vivo Results – PF2

    In Vivo Results – PF2 Platelet Activation Pump implant Sham surgery

  20. Slide 20: PediaFlow/MiFlow – Blood Damage Modeling

    PediaFlow/MiFlow – Blood Damage Modeling *Scaled from NIH measurements

  21. Slide 21: In Vivo Results – PF3

    In Vivo Results – PF3 Post-explant device analysis Implant duration – 72 Days No deposition on pump surfaces; kidneys free of infarcts

  22. Slide 22: Blood Path Comparison

    VAD Blood-Contacting Area (cm 2 ) Priming Volume (ml) Annular Gap Cross-section (mm 2 ) Blood Path Comparison Levacor 20.7 -- MiFlow 3.4 PediaFlow PF3 2.3 MiFlow and PediaFlow PF4 rotors (SLA components for in vitro testing) - Blood paths for PediaFlow and MiFlow are similar

  23. Slide 23: MiFlow Miniaturized VAD - Pump Cross-Section

    MiFlow Miniaturized VAD - Pump Cross-Section Inflow Outflow Stator blades Permanent magnet radial support Motor stator Voice coil Motor magnets Axial magnets Impellor blades

  24. Slide 24: Streamlines

    Streamlines Miniaturized VAD – CFD Evaluation Q=5.0L/min, 14K rpm

  25. Slide 25: MiFlow – Size Comparison

    MiFlow – Size Comparison HeartMate II MiFlow 19 mm 21 mm

  26. Slide 26: MiFlow – Size Comparison

    MiFlow – Size Comparison 19 mm 21 mm 21 mm 25 mm HeartMate II HVAD Jarvik 2000 MiFlow 63 cc, 281 gms 50 cc, 145 gms 25 cc, 90 gms 20 cc, 65 gms

  27. Slide 27: Miniaturized VAD Configuration – w/ perc lead

    Minaturized VAD Configuration – w/ perc lead Outflow to descending aorta Experience with Jarvik 2000 1,2 validates this anatomic placement 1- Frazier OH. Implantation of the Jarvik 2000 LVAD without use of CPB. Ann Thor Surg 2003:75:1028-30 2-Selzman HC. Off-Pump Insertion of the Jarvik 2000 LVAD. C

  28. Slide 28: Development Timeline – MiFlow VAD

    Development Timeline – MiFlow VAD Development costs estimated to $35M (perc lead configuration)

  29. Slide 29: Financial Summary

    Financial Summary Cash Balance (3/31/11) $17.7M Monthly Cash Burn $1.2M-$1.3M 52 Week Stock Price (High and Low) * $3.26-$.45 Shares Outstanding 26.7M Options Outstanding 2.1M Warrants Outstanding 13.3M * As of 8/1/11

  30. Slide 30: Strong Intellectual Property Protection

    Strong Intellectual Property Protection Strong IP position for single-active axis Maglev rotary pump IP focused on latest-generation technologies (bearingless, magnetically levitated/driven) Rotary pumps (Levacor, PediaFlow, MiFlow) – 15 issued patents (13 owned or exclusively licensed, 2 non-exclus

  31. Slide 31: WorldHeart Highlights

    WorldHeart Highlights Two advanced Ventricular Assist Device programs MiFlow TM VAD – Fully magnetically levitated miniature rotary blood pump; designed to provide long-term circulatory support for earlier-stage heart failure with minimally invasive implant PediaFlow® – Fully magnetically levitated

  32. Slide 32: End

    End

World Heart — Investor Presentation (August 2011) on 6ix